Literature DB >> 8473155

Multifactorial study of inflammatory myopathies. Report of 29 cases.

C Angelini1, E Menegazzo, M Fanin.   

Abstract

We made a comparative clinical, immunopathological and therapeutic evaluation in 17 patients with polymyositis (PM) and 12 patients with dermatomyositis (DM), followed up at our Neuromuscular Center. DM can be distinguished by its clinical appearance and pathological changes. Current evidence suggests that it results from vasculopathy. For studying these inflammatory myopathies we used multifactorial diagnostic criteria, evaluating the therapeutic response by means of a composite clinical and functional score in a longitudinal study. In muscle biopsy specimens we characterized with monoclonal antibodies T lymphocyte subpopulations (CD4, CD8), macrophages, IgG, IgM, C1q, C3, C4 complement fractions, MHC-I, MHC-II. In PM the cell-mediated immunity was more pronounced and in some cases both MHC-I and MHC-II molecules were found on the surface or within muscle fibers. Our patients were treated with steroids; in resistant cases azathioprine, cyclophosphamide, plasmapheresis, high-dose intravenous immunoglobulins (ivIgG) and total body irradiation were added to the therapeutic schedule.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473155     DOI: 10.1007/BF02339045

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  18 in total

1.  Induction of HLA-DR expression on human myoblasts with interferon-gamma.

Authors:  R Hohlfeld; A G Engel
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

Review 2.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

3.  Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies.

Authors:  A G Engel; K Arahata
Journal:  Hum Pathol       Date:  1986-07       Impact factor: 3.466

4.  Remission from polymyositis after total body irradiation.

Authors:  W N Hubbard; M J Walport; K E Halnan; R P Beaney; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-26

5.  Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.

Authors:  A M Emslie-Smith; K Arahata; A G Engel
Journal:  Hum Pathol       Date:  1989-03       Impact factor: 3.466

6.  Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration.

Authors:  A M Emslie-Smith; A G Engel
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

7.  Elevated MHC class I and II antigens in cultured human embryonic myoblasts following stimulation with gamma-interferon.

Authors:  S S Bao; N J King; C G dos Remedios
Journal:  Immunol Cell Biol       Date:  1990-08       Impact factor: 5.126

8.  Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients.

Authors:  P C Dau
Journal:  Arch Neurol       Date:  1981-09

9.  Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma.

Authors:  R Mantegazza; S M Hughes; D Mitchell; M Travis; H M Blau; L Steinman
Journal:  Neurology       Date:  1991-07       Impact factor: 9.910

10.  Expression of immunoreactive major histocompatibility complex products in human skeletal muscles.

Authors:  G Karpati; Y Pouliot; S Carpenter
Journal:  Ann Neurol       Date:  1988-01       Impact factor: 10.422

View more
  1 in total

1.  The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors:  Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.